mobile-banner

Benefit of 2-in-1

AKEEGA® is an FDA-approved targeted therapy that combines PARPi/NHT into a single tablet1

Simplified dosing in a once-daily* dual action tablet

checkmark

2 THERAPIES

checkmark

1 CO-PAY

checkmark

1 PRIOR AUTHORIZATION

The recommended AKEEGA® dose is 200 mg niraparib/1,000 mg abiraterone acetate

2-in-1 Dual Action Tablet with niraparib and abiraterone acetate infographic2-in-1 Dual Action Tablet with niraparib and abiraterone acetate infographic

*AKEEGA® is indicated with 5 mg prednisone daily for patients with mCSPC.

Flexible dosing

AKEEGA® offers your patients 2 strengths for dosing flexibility and adjustments as needed1†‡

100mg/500mg

+

100mg/500mg

+

5mg

AKEEGA® recommended dose

200 mg/1,000 mg (niraparib/
abiraterone acetate) once daily with 5 mg of prednisone daily

50 mg/500 mg

+

50 mg/500 mg

+

5mg

AKEEGA® reduced-dose options for specific adverse reactions
2 lower-strength (50 mg/500 mg) niraparib/
abiraterone acetate once daily with 5 mg of prednisone daily

-OR-

100 mg/500mg

+

5mg

1 regular-strength (100 mg/500 mg) niraparib/
abiraterone acetate once daily with 5 mg of prednisone daily

†Patients receiving AKEEGA® should also receive a GnRH analog concurrently or should have had bilateral orchiectomy.1

‡See full Prescribing Information for guidance on dosage modification for adverse reactions with AKEEGA®.

Administration

The recommended dose of AKEEGA® is 200 mg niraparib/1,000 mg abiraterone acetate (two 100 mg/500 mg tablets)1§

Double pill icon

AKEEGA® tablets must be taken orally as a single dose once a day

Not with food icon

AKEEGA® should be taken on an empty stomach at least 1 hour before or 2 hours after food

Take with water icon

The tablets must be swallowed whole with water. Advise patients not to crush or chew tablets

Target with arrow icon

If a dose of AKEEGA® or prednisone is missed, instruct patients to take the dose as soon as possible on the same day and to return to the normal schedule the following day

No extra dose icon

Extra tablets must not be taken to make up for the missed dose

§AKEEGA® is indicated with 5 mg prednisone daily for patients with mCSPC. Patients receiving AKEEGA® should also receive a GnRH analog concurrently or should have had bilateral orchiectomy.1

See results from the AMPLITUDE trial
Learn how your patients can access AKEEGA®

AR, androgen receptor; DNA, deoxyribonucleic acid; FDA, U.S. Food and Drug Administration; GnRH, gonadotropin-releasing hormone; mCSPC, metastatic castration-sensitive prostate cancer; NHT, novel hormonal therapy; PARP, poly (ADP-ribose) polymerase; PARPi, poly-ADP ribose polymerase inhibitor.

References:

  1. AKEEGA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. Schiewer MJ, Goodwin JF, Han S, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2(12):1134-1149. doi:10.1158/2159-8290.CD-12-0120
  3. Teyssonneau D, Margot H, Cabart M, et al. Prostate cancer and PARP inhibitors: progress and challenges. J Hematol Oncol. 2021;14(1):51.0 doi:10.1186/s13045-021-01061-x